CreatorsPublishersAdvertisers
View more in
Cancer

Dr. Rosenberg on Adapting Treatment Decisions Based on MRD in Multiple Myeloma

onclive.com
 2021-07-28

Aaron Seth Rosenberg, MD, MS, discusses the emerging role of minimal residual disease to guide treatment decisions in multiple myeloma. Aaron Seth Rosenberg, MD, MS, associate professor, Department of Internal Medicine, Division of Hematology and Oncology, UC Davis Health, discusses the emerging role of minimal residual disease (MRD) to guide treatment decisions in multiple myeloma.

www.onclive.com

Comments / 0

Comments / 0